Association of Extended Dosing Intervals or Delays in Pembrolizumab-Based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer

Bulumulle, AnushiBrody, HeatherMacherla, ShravantiWalker, Paul R.Sehgal, KartikGill, Ritu R.Qilleri, AleksandraMcDonald, Danielle C.Cherry, Cynthia R.Shea, MeghanHuberman, Mark S.VanderLaan, Paul A.Weiss, Glen J.Costa, Daniel B.Rangachari, Deepa2022-10-132022-10-1320211525-7304http://hdl.handle.net/10342/11510en-USDosing IntervalsSurvival OutcomesNonesmall-cell Lung CancerAssociation of Extended Dosing Intervals or Delays in Pembrolizumab-Based Regimens With Survival Outcomes in Advanced Non-small-cell Lung CancerArticle10.1016/j.cllc.2020.05.028